Allurion Technologies (ALUR) Stock
Publicly traded company. Here's the price, business snapshot, and what's worth knowing about Allurion Technologies in November 2026.
Allurion Technologies is a medical-device company focused on non-surgical weight-loss solutions, most notably a swallowable gastric balloon and a digital programme to support patient weight management. The company operates in the obesity-treatment segment, combining a device with remote monitoring and clinical services. For investors this is a micro-cap idea: market capitalisation is small and liquidity can be limited, which tends to increase share-price volatility and execution risk. Potential attractions include exposure to a growing global demand for less-invasive obesity therapies and the possibility of scaling via clinic partnerships, tech-enabled follow-up and new markets. Key risks include regulatory and clinical outcomes, competition from established device makers and drug therapies, uncertain revenue visibility and the potential need for additional financing. This summary provides general educational information only and is not personal advice. Values can rise and fall; investors should assess company filings, clinical data and market dynamics, and consider suitability for their own risk tolerance.
Allurion Technologies (ALUR) Stock Forecast
Analyst price target, next 12 months
$5.25
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Allurion's stock with a target price of $5.25, indicating strong growth potential.
Financial Health
Allurion Technologies is performing well with good revenue and cash flow, showing strong profitability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ALUR
Obesity Drug Distribution via Telehealth Platforms Explained
Novo Nordisk has launched a discounted telehealth subscription model for its popular Wegovy treatments to counter rising competition. This shift creates compelling investment opportunities in the digital health platforms that are becoming vital distribution channels for blockbuster obesity drugs.
Published: 1 April 2026
Explore BasketBiotech Buyout Wave Targets Obesity Market 2025
Pfizer's bid for obesity drug maker Metsera has turned into a legal battle after a counteroffer from Novo Nordisk, highlighting the fierce competition in the weight-loss market. This intense M&A activity signals that other biotech companies with promising obesity treatments could become the next valuable acquisition targets.
Published: 1 November 2025
Explore BasketWeight-Loss Drug M&A: Valuation Risk Concerns
Novo Nordisk's superior bid for Metsera has ignited a bidding war with Pfizer, highlighting the intense M&A activity in the obesity drug market. This theme focuses on other biotech companies with promising weight-loss therapies that could become the next acquisition targets.
Published: 31 October 2025
Explore BasketThe Global Weight-Loss Drug Price Shift
Eli Lilly's significant price hike for Mounjaro in the UK, driven by U.S. political pressure, highlights a new global pricing strategy for blockbuster drugs. This creates a potential opportunity for competitors in the booming weight-loss market as patients and providers may seek more affordable alternatives.
Published: 15 August 2025
Explore BasketExecutive Conviction In The GLP-1 Market
Following a stock drop from a clinical trial setback, Eli Lilly executives made significant share purchases, signaling strong belief in the company's future. This insider confidence highlights a potential investment opportunity in the rapidly growing and competitive GLP-1 weight-loss drug market.
Published: 13 August 2025
Explore BasketWhy You’ll Want to Watch This Stock
Market opportunity
Obesity treatment is a growing global market and less-invasive options attract interest; however, adoption can be gradual and revenue growth is not guaranteed.
Device plus software
Combining a physical device with remote monitoring and digital care can create differentiated services, though clinical outcomes and reimbursement matter for uptake.
Scale and risks
International clinic partnerships offer expansion potential, but small market cap and regulatory hurdles mean execution and financing risks are material.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.